RT ASX (@asx_capital)We are excited to officially announce our next RWA, Franklin Jefferson Candlelight Apartments!Some details:APR: 8.5% 🔥🔥Total Raise: $50,000Date: TBDSee all the details on our RWA page:https://t.co/I76T77YovE ...

Investment Rating - The report maintains an "Outperform" rating for the non-bank financial sector, indicating an expected performance that exceeds the broader market index by over 10% [12]. Core Insights - The Hong Kong Monetary Authority (HKMA) has announced the implementation of regulatory guidelines for stablecoin issuers, with a focus on strict initial licensing measures and a controlled number of licenses to be issued in 2025 [5][6]. - The regulatory framework emphasizes anti-money laundering (AML) and know your customer (KYC) protocols, requiring applicants to maintain high liquidity reserves and a minimum paid-up capital of HKD 25 million [5][6]. - The licensing process is designed to be stringent, with a requirement for applicants to submit a comprehensive set of documents and to consult with the HKMA prior to application [6]. Summary by Sections Regulatory Developments - The HKMA's stablecoin regulations will take effect on August 1, 2025, with a limited number of licenses to be issued in the initial phase [5]. - Existing stablecoin issuers must apply for licenses by October 31, 2025, or face a winding-up period starting November 1, 2025 [6]. Investment Recommendations - The report suggests focusing on companies that have already obtained virtual asset trading licenses, such as Cathay Securities and fintech-related firms, as well as brokerages that are expanding into virtual asset services, including CITIC Securities and Huatai Securities [7].

Cryptocurrency Investment & Market Dynamics - Locked primary market investments rarely outperform Bitcoin, primarily due to attention dynamics [1] - Altcoins' ability to attract attention diminishes post-Token Generation Event (TGE), leading to significant devaluation of paper wealth [1] - Projects have limited opportunities to capture attention post-TGE, with the initial 3 days after launch being crucial [1] Project Execution & Resource Allocation - Projects often struggle post-TGE due to financial constraints or lack of execution capabilities, with a correlation between financial resources and execution ability [1] - Kaia Chain's ability to implement initiatives like offline ATM cash withdrawals demonstrates strong execution and financial capacity [1] - Stablecoin and Real World Asset (RWA) businesses offer profit potential, but require significant resources and capabilities to succeed [1]

Core Insights - Huajian Medical (01931) has signed a strategic cooperation framework agreement with BGI CoWin to establish the "Huajian-BGI CoWin Innovative Drug Intellectual Property Tokenization Fund" aimed at investing in Web3 exchange ecosystem projects in Hong Kong and the US [1][6][7] - Following the announcement, Huajian Medical's stock price surged by 15.78%, nearing HKD 5 per share, with a market capitalization reaching HKD 8 billion [3][6] - The fund will address long-standing industry challenges by tokenizing high-value medical assets, allowing ordinary investors access to clinical-stage drug development [6][10] Group 1: Fund Structure and Strategy - The framework agreement outlines that Huajian Medical or its designated entity will act as a limited partner, while BGI CoWin will serve as the general partner responsible for fund management [7] - The fund aims to leverage BGI CoWin's resources in innovative medical projects to select high-quality targets for investment [7][9] - The establishment of the fund coincides with a significant recovery in the innovative drug capital market, with 18 companies in the healthcare sector successfully listing and raising over 18 billion yuan in the first half of the year [7][10] Group 2: Web3 Ecosystem Development - The fund represents a key component of Huajian Medical's "NewCo + RWA + Stablecoin" strategy, which aims to reshape the global value chain of innovative drug assets [8][9] - BGI CoWin will provide comprehensive services from due diligence to transaction design for selected pharmaceutical companies or target assets [9] - Huajian Medical has registered a wholly-owned subsidiary in New York and is applying for stablecoin licenses, positioning itself advantageously in the regulatory landscape [9][10] Group 3: Market Potential and Innovation - The global RWA market is projected to reach USD 16.1 trillion by 2030, representing 10% of global GDP, with innovative drug asset tokenization having inherent advantages [10][11] - The traditional pharmaceutical R&D model faces liquidity challenges, with 80% of funding consumed during clinical stages, excluding ordinary investors [10][11] - Huajian Medical's strategy focuses on the medical innovation drug sector, aiming to create a "global free trading market" for innovative drug assets through its three-tiered structure [10][11] Group 4: Brand Transformation - Huajian Medical announced a brand upgrade alongside the fund's establishment, redefining its core brand "IVD" to emphasize Innovation, Verification, and Development [12][13] - The new logo symbolizes the company's vision of transforming from a medical device distributor to a builder of a decentralized scientific ecosystem [12][13] - The ultimate goal is to enable top-tier medical innovative drug IP to circulate freely like digital currency, creating a positive cycle among capital, R&D, and commercialization [12][13]

Core Viewpoint - 华检医疗 has signed a strategic cooperation framework agreement with 华大共赢 to establish the "华检华大共赢创新药知识产权代币化基金," aimed at investing in Web3 exchange ecosystem projects in Hong Kong and the US [1][6]. Group 1: Fund Establishment and Market Context - The newly established fund will be managed by 华大共赢, which will act as the general partner, while 华检医疗 will contribute as a limited partner [7]. - The fund's creation coincides with a significant recovery in the innovative drug capital market, with 18 companies in the healthcare sector successfully listing and raising over 18 billion yuan in the first half of the year [7]. - The innovative drug sector has become a hot investment area, with the 中证港股通创新药指数 increasing by over 124% since the beginning of the year [7]. Group 2: Web3 Strategy and Ecosystem - The fund represents a key component of 华检医疗's "NewCo+RWA+stablecoin" strategy, which aims to reshape the global medical innovation drug asset value chain [9]. - 华大共赢 will provide comprehensive services from due diligence to transaction design for selected innovative pharmaceutical companies or target assets [9]. - The ecosystem includes the "IVDNewCo Exchange" trading platform and the proprietary stablecoin IVD Dollar (IVDD), with regulatory applications already initiated in the US and Hong Kong [9][10]. Group 3: Market Potential and Value Chain Reconstruction - The global RWA market is projected to reach $16.1 trillion by 2030, representing 10% of global GDP, with innovative drug asset tokenization having inherent advantages [11]. - The traditional pharmaceutical R&D model faces liquidity issues, with 80% of funding consumed during clinical phases, excluding ordinary investors [11]. - 华检医疗's approach focuses on the medical innovation drug sector, aiming to create a "global free trading market" through its three-tiered structure [11][12]. Group 4: Brand Transformation - 华检医疗 announced a brand upgrade alongside the fund's establishment, redefining its core brand "IVD" to emphasize Innovation, Verification, and Development [13][14]. - The new logo symbolizes the company's vision of enabling top medical innovation drug IP to circulate freely like digital currency [14][15].

Crypto Platform Capabilities - The platform aims to support a wide range of crypto assets and functionalities, including Real World Assets (RWAs), smart contracts, and stablecoins [1] - The platform positions itself as superior to centralized exchanges (CEXs) by supporting decentralized exchanges (DEXs) [1] Metaphorical Description - The platform uses the metaphor of a "shishkabob of crypto" to illustrate its comprehensive support for various crypto elements [1]

RT Morgan Krupetsky (@MorganKrupetsky)Welcoming @grovedotfinance to the Avalanche ecosystem, along with OG RWA platform @centrifuge.I've been especially excited about this partnership for a while. Back when I met @kevinlichan from his days at BlockTower Credit, I remember being struck by our mutual belief in how on-chain ecosystems could truly revolutionize & upgrade legacy financial infrastructure. It's rare to find partners so aligned in that vision.Today, that shared vision culminates in a momentous step ...

Plume’s growth is insane.Right now: 500K → 2M txns/day,$200M → $300M TVL.RWAs finally feel like they’re clicking.This might actually be the RWAfi moment. https://t.co/GHLn44b4gT ...

综合市场分析来看，金融科技回调下挫或与香港稳定币牌照落地不及预期有关。消息面上，香港《稳定 币条例》将于8月1日实施，7月29日下午，香港金管局披露了稳定币发行人相关监管制度。其中提到， 截至目前，尚未发出任何稳定币发行人牌照，未来将在官网公布获发牌照的稳定币发行人名单。 中信证券解读称，时间线上看，金管局鼓励意向申请人于8月31日前联系监管，成熟申请人申请时限为9 月30日，首批牌照张数仅个位数，预计有望于年底前落地。建议继续关注可能获取首批稀缺牌照的发行 人，及确定性参与稳定币使用场景创设的场景平台两条主线。 周三（7月30日），稳定币、跨境支付等热门题材悉数调整，高位人气股下挫，金融科技板块深度回 调，成份股大面积飘绿。其中，东信和平跌停，天阳科技、四方精创、恒宝股份均下挫超7%，长亮科 技、金证股股份、中科金财、拉卡拉、京北方、中亦科技等跟跌超5%。 热门ETF方面，规模、流动性同类断层第一的金融科技ETF（159851）放量下挫，场内价格收跌3.3%， 跌穿5日、10日均线，退守20日均线。全天成交额达12.75亿元，环比放量超五成！资金逢跌大举揽筹， 159851全天净申购达4.38亿份！ 数据来 ...

Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase of over 16% following the announcement of a successful multi-billion yuan revolving loan obtained by its subsidiary, Weishida, from a banking syndicate led by East Asia Bank's Shanghai branch [1] Group 1: Financial Developments - The revolving loan involves participation from seven financial institutions, including Mitsui Sumitomo, Shengjing Bank, and Busan Bank of Korea [1] - The stock price rose by 16.31%, reaching HKD 4.35, with a trading volume of HKD 15.16 million [1] Group 2: Strategic Initiatives - On July 17, the company announced the establishment of the "IVDNewCo Exchange," a Web3 ecosystem focused on high-tech medical innovation assets, along with the issuance of a proprietary stablecoin, IVD Dollar (IVDD) [1] - On July 20, Huajian Medical registered a wholly-owned subsidiary, IVD GROUP INC., in New York, and initiated the application for stablecoin licenses with the SEC and CFTC [1] Group 3: Market Positioning - The "IVDNewCo Exchange" aims to address significant pain points in the pharmaceutical industry, where new drug development typically takes 10 years and 80% of funding is spent in clinical stages, while ordinary investors are often excluded [1] - The company’s strategy involves converting high-value medical assets, such as phase II clinical ADC drugs and gene therapy patents, into tradable digital certificates through RWA technology [1] - Huajian Medical aims to become the "Nasdaq + Uniswap" of the medical RWA sector, ensuring compliance while achieving decentralized liquidity, leveraging its first-mover advantage in a niche market [1]